Wedbush keeps Outperform rating on Disc Medicine with $110 price target
Wedbush analysts kept an Outperform rating on Disc Medicine and a $110 target, implying a 39.4% upside from the October 19 close.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, citing Benzinga data, Wedbush kept its Outperform recommendation on Disc Medicine shares and set a $110 price target. The target implies a 39.4% upside from the October 19 close, when the stock stood at $78.93.
The analyst note highlights the company's pipeline, including bitopertin and DISC-0974, aimed at erythropoietic porphyrias and anemia of myelofibrosis. It also cites Merck KGaA's $1.1 billion acquisition of Silence Therapeutics, made after positive data for a competitor's treatment in polycythemia vera, as an external benchmark for valuing DISC-3405.
why it matters
For investors, this is mainly one brokerage's view rather than a market-wide event. Deals in related areas can shape how biotech companies are valued, so Disc Medicine is often compared with similar assets. The rating alone does not change the company's underlying fundamentals.
tags
instruments
sources
- Wedbush maintains Outperform rating on Disc Medicine, $110 price target — TradingView, 20 October 2026 at 12:34 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗